DGAP-Adhoc: STADA Arzneimittel AG: Successfully concluded purchase of the Russian branded product portfolio Aqualor(R) for the self-medication of sinusitis and sore throat


STADA Arzneimittel AG  / Key word(s): Miscellaneous

28.02.2014 13:37

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Vilbel, February 28, 2014 - Today, on February 28, 2014, the Russian
subsidiary of STADA Arzneimittel AG, OAO Nizhpharm, successfully concluded
the purchase of the Russian branded product portfolio Aqualor(R) (see ad
hoc release of October 18, 2013 on the signing of the framework agreement
for the purchase).

The branded product portfolio will be consolidated in the STADA Group as of
March 1, 2014. 


Additional information: 
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / 61118
Bad Vilbel - Germany / Phone: +49(0) 6101 603-113 / Fax: +49(0) 6101
603-506 / E-Mail: communications@stada.de / Or visit us in the Internet at
www.stada.com


28.02.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      STADA Arzneimittel AG
              Stadastraße 2-18
              61118 Bad Vilbel
              Germany
Phone:        +49 (0)6101 603- 113
Fax:          +49 (0)6101 603- 506
E-mail:       communications@stada.de
Internet:     www.stada.de
ISIN:         DE0007251803, DE0007251845, 
WKN:          725180, 725184, 
Indices:      MDAX
Listed:       Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
              Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------